{
  "event_id": "fb30fee0e11c",
  "ticker": "PFE",
  "company_name": "Pfizer",
  "drug_name": "BEQVEZ fidanacogene elaparvovec-dzkt",
  "pdufa_date": "2024-04-30",
  "approval_type": {
    "status": "found",
    "value": "bla",
    "source": "websearch:BENEGENE-2 Phase 3",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:39.969483",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Hemophilia B gene therapy",
    "source": "websearch:BENEGENE-2 Phase 3",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:39.969484",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "fidanacogene elaparvovec-dzkt",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:05:16.351049",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Gene Therapy",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:59.009990",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Phase 3",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:05:16.351049",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:BENEGENE-2 Phase 3",
    "confidence": 0.95,
    "evidence": [
      "BENEGENE-2 Phase 3"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:39.969470",
    "error": null
  },
  "p_value": {
    "status": "found",
    "value": "<0.0001",
    "source": "websearch:BENEGENE-2 Phase 3",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:39.969477",
    "error": null
  },
  "p_value_numeric": 0.0001,
  "effect_size": {
    "status": "found",
    "value": "77% ABR reduction; 95% prophylaxis-free at year 2",
    "source": "websearch:BENEGENE-2 Phase 3",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:39.969480",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "Gene Therapy, Open-label, Dose-escalation Study of PF-06838435 (SPK-9001) [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B",
    "A FACTOR IX (FIX) GENE TRANSFER, MULTI CENTER EVALUATION OF THE LONG TERM SAFETY AND EFFICACY STUDY OF PF 06838435 AND A DOSE ESCALATION SUBSTUDY IN INDIVIDUALS WITH HEMOPHILIA B",
    "AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SAFETY DATA OF FACTOR IX OR FACTOR VIII PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C≤2%) WHO ARE NEGATIVE FOR nAb TO AAV VECTOR-SPARK100 AND MODERATELY SEVERE TO SEVERE HEMOPHILIA A ADULT SUBJECTS (FVIII:C≤1%) WHO ARE NEGATIVE FOR nAb TO AAV VECTOR SB-525 CAPSID (AAV6), PRIOR TO THE RESPECTIVE THERAPEUTIC PH 3 GENE THERAPY STUDIES (See Detailed Description Section for Official Protocol Title)",
    "Phase 3, Open-label, Single-arm Study to Evaluate Efficacy and Safety of FIX Gene Transfer With PF-06838435 (rAAV-Spark100-hFIX-R338L) in Adult Male Participants With Moderately Severe to Severe Hemophilia B (FIX:C ≤2%) (BeneGene-2)",
    "A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY"
  ],
  "nct_ids": [
    "NCT02484092",
    "NCT03307980",
    "NCT03587116",
    "NCT03861273",
    "NCT05568719"
  ],
  "enrollment": {
    "count": 212,
    "type": "ACTUAL",
    "nct_id": "NCT03587116",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:29:31.824141"
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": 0,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:23:41.021106",
  "enriched_at": "2026-01-11T19:57:37.298610",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "6bedef85f5ee",
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": true,
    "accelerated_approval": false
  },
  "mechanism_of_action": "AAV gene therapy",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -620,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:41.498890",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:43:41.747030"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:43:41.747038"
  },
  "breakthrough_therapy": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:57:17.529131",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:57:22.429614",
    "search_status": "CONFIRMED_NONE"
  },
  "priority_review": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:57:27.451955",
    "search_status": "CONFIRMED_NONE"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:57:32.424377",
    "search_status": "CONFIRMED_NONE"
  },
  "accelerated_approval": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:57:37.298593",
    "search_status": "CONFIRMED_NONE"
  }
}